

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

(11) Publication number:

**0 070 685**  
**A2**

(12)

# EUROPEAN PATENT APPLICATION

(21) Application number: 82303699.1

(51) Int. Cl.: **G 01 N 33/58**

(22) Date of filing: 14.07.82

(30) Priority: 17.07.81 US 284469

(71) Applicant: Standard Oil Company, 200 East Randolph Drive, Chicago Illinois 60601 (US)

(43) Date of publication of application: 26.01.83  
Bulletin 83/4

(72) Inventor: Heller, Michael James, 30 W 057-104 Granada, Naperville Illinois 60540 (US)  
Inventor: Morrison, Larry Edward, 4913 Spencer, Lisle Illinois 60532 (US)  
Inventor: Prevatt, William Dudley, 1205 Grant Street, Downers Grove Illinois 60515 (US)  
Inventor: Akin, Cavit, 1462 Inverrary Drive, Naperville Illinois 60540 (US)

(64) Designated Contracting States: BE CH DE FR GB IT LI NL

(74) Representative: Ritter, Stephen David et al, Mathys &amp; Squire 10 Fleet Street, London EC4Y 1AY (GB)

(54) Homogeneous nucleic acid hybridization diagnostics by non-radiative energy transfer.

(57) A homogeneous light-emitting hybridization assay is disclosed wherein light-labeled first and second single-stranded reagent segments are hybridized with a complementary target single-stranded polynucleotide from a physiological sample such that non-radiative energy transfer occurs between the light labels of the two reagent segments. At least one of the light labels is of the absorber/emitter type such that energy absorbed from the other light label is re-emitted as a different wavelength. Such secondary emissions can only occur if hybridization has taken place and hence the presence of the target polynucleotide is related to the amount of secondary light emitted.

**EP 0 070 685 A2**

HOMOGENEOUS NUCLEIC ACID HYBRIDIZATION  
DIAGNOSTICS BY NON-RADIATIVE ENERGY TRANSFER

BACKGROUND OF THE INVENTION

5           Presently, nucleic acid hybridization assays  
are used primarily in the field of molecular  
biology as a research tool for the detection and  
identification of a unique deoxyribonucleic acid  
(DNA) sequence or specific gene in a complete DNA,  
10       a mixture of DNA's, or mixture of DNA fragments. A  
number of variations of the technique exist and are  
used in recombinant DNA research. . (See Methods in  
Enzymology, Vol. 68, R. Wu (Ed.) pp. 379-469, 1979;  
and Dunn, A. R., and Sambrook, J., Methods in  
15       Enzymology, Vol. 65; Part 1, pp. 468-478, 1980.)  
One of the most widely used procedures is called  
the Southern blot filter hybridization method  
(Southern, E., J. Mol. Biol. 98, 503, 1975). This  
procedure is usually used to identify a particular  
20       DNA fragment separated from a mixture of DNA fragments  
by electrophoresis. The procedure is generally  
carried out by isolating a sample of DNA from some  
organism. The isolated DNA is subjected to  
restriction endonuclease digestion and  
25       electrophoresed on a gel (agarose, acrylamide,  
etc.). When the gel containing the separated DNA  
fragments is put in contact (blotted) with a  
nitrocellulose filter sheet (or diazotized paper,  
etc.), the fragments are transferred and become  
30       bound to the nitrocellulose sheet. The gel-transfer  
nitrocellulose sheet containing the DNA fragments  
is then heated (~95°C) to denature the DNA. At  
this point the sheet is treated with a solution  
containing denatured radiolabeled (<sup>32</sup>P) "specific  
35       DNA probe" and hybridization is allowed to take  
place. Hybridization can take from 3-48 hours,  
depending on given conditions. Unhybridized

"specific DNA probe" is then washed away. The nitrocellulose sheet is placed on a sheet of X-ray film and allowed to expose, which usually takes several days at  $-70^{\circ}\text{C}$ . The X-ray film is then developed. The exposed areas on the film identify which DNA fragments have hybridized and therefore have a sequence similar to that of the "specific DNA probe." This procedure, as well as most other variations, requires the use of radioisotopes and is obviously very complex and time consuming. Because of these and other problems, DNA hybridization assays have remained only as a tool for basic research and have not been generally used in applied or commercial areas such as for clinical diagnostics.

By way of further background, the phenomenon of non-radiative energy transfer has also been utilized as an analytical tool. It occurs when one light emitting species is very close to another species which absorbs light energy within the emission spectrum of the emitting species. This energy transfer is most closely approximated by the Forster equation. (See "Energy Transfer and Organic Photochemistry" Vol. XIV, P. A. Leemakers and A. Weissberger, pp. 17-132, (1969), Interscience, New York.) The use of the non-radiative energy concept has been described in a number of patents in connection with immunofluorescent assays. (See U.S. Patent Nos. 3,996,345; 3,998,943; 4,160,016; 4,174,384; and 4,199,559, all issued to E. F. Ullman or Ullman and M. Schwarzberg.) These patents are closely related and generally pertain to assays wherein the fluorescent light emitted from an irradiated sample is diminished in the presence of a species (quencher) which absorbs some of the light energy. For a similar discussion, see "Fluorescent Excitation Transfer Immunoassay", The

Journal of Biological Chemistry, Vol. 251, No. 14,  
pp. 4172-4178 (July 25, 1976). Also see

"Fluorescamine and Fluorescein as Labels in Energy-  
Transfer Immunoassay," Analyst, Vol. 105, pp. 91-92

- 5 (January 1980). In addition, energy-transfer techniques  
have been used to determine the tertiary structure  
of transfer RNA's (C-H Yang and D. Solinas,  
Vol. 71, No. 7, pp. 2838-2842, 1974).

- There is a definite need in the area of  
10 clinical diagnostics for a simple and rapid method  
for detecting and identifying unique nucleotide  
(genome) sequences. For example, many so-called  
"slow infection" diseases of humans and animals  
where symptoms appear long after the infectious  
15 process is initiated are caused by virus or virus-  
like agents. Some of these diseases include Kuru,  
Creutzfeldt-Jakob disease, subacute sclerosing  
panencephalitis, and progressive multifocal  
leukoencephalopathy. There is also evidence that  
20 more common human diseases, such as multiple sclerosis  
(MS) may be slow infections caused by measles virus.  
In many cases the viral agents believed to cause  
these slow infection diseases cannot be detected by  
immunodiagnostic techniques because no viral  
25 antigens are presents. Therefore, hybridization  
assays are used to directly detect the viral genome  
(A. T. Haase, et al. Science, 212, pp. 672-674,  
1981). Hybridization assays would also be useful  
in determining antibiotic resistance traits of many  
30 pathogenic microorganisms through detection of the  
resistance factor genome. Thus, hybridization  
diagnostics could play an important role in any  
case where low or no antigenic response precludes  
the use of immunodiagnostic techniques. However,  
35 for wide spread commercial use in clinical diagnostics,  
such a hybridization method should be relatively  
fast, simple to carry out, highly specific, highly

sensitive, and if possible not involve the use of radioisotopes. Presently such a method is not available.

#### SUMMARY OF THE INVENTION

5           In general, the invention relates to a homogeneous hybridization assay which is based on the inherent high fidelity of the base recognition process in double-stranded (ds) polynucleotides (DNA, RNA, DNA-RNA and synthetic polynucleotides)  
10           and the phenomenon of non-radiative energy transfer. It also relates to a hybridization system that does not involve the use of radioisotopes, but instead involves a chemiluminescent catalyst and an absorber/emitter moiety, which under proper conditions  
15           can provide sensitivity equal to that of radioisotopes. Most importantly it involves the use of two polynucleotide reagent strands in such a way that the hybridization assay is carried out in a homogeneous fashion. This means target polynucleotide sequences  
20           can be detected and identified in solution without the need to carry out any immobilization procedures. Also, because complete hybridization is necessary in order to produce the appropriate energy transfer generated light signal for detection, this method  
25           can be much more selective than any method presently available.

          In one aspect, the invention resides in a diagnostic method for determining the presence of viruses, bacteria, and other microorganisms, as  
30           well as the existence of certain genetic expressions, by assaying for a particular single-stranded (ss) polynucleotide sequence which is characteristic of the target microorganism or genetic expression being assayed. In particular, the method comprises  
35           contacting the sample, under hybridization conditions, with first and second ss-polynucleotide reagent segments which are complementary to

substantially mutually exclusive portions of the target ss-polynucleotide, said first reagent segment having a chemiluminescent catalyst and said second reagent segment having an absorber/emitter moiety

5 positioned such that, upon hybridization with a target ss-polynucleotide, the chemiluminescent catalyst and the absorber/emitter moiety are close enough in proximity to permit non-radiative energy transfer (generally within about 100A or less of  
10 each other); further contacting the sample with agents effective for inducing light emission from the chemiluminescent catalyst; and measuring the quantity of light emitted by the absorber/emitter catalyst to determine amount of hybridization.

15 In a further aspect the invention resides in the foregoing method wherein the first ss-poly-nucleotide reagent segment also has an absorber/emitter moiety which absorbs a shorter wavelength of light than the absorber/emitter  
20 moiety on the second reagent segment, but emits light in a wavelength region that overlaps with the absorbance region of the absorber/emitter moiety on the second reagent segment. The hybridized sample is then irradiated with light of appropriate wave-  
25 length to excite the absorber/emitter moiety on the first reagent segment and the amount of hybridization is determined by measuring the quantity of light emitted from the absorber/emitter on the second reagent segment.

30 In a further aspect, the invention resides in the reagents useful in carrying the methods described.

The term "absorber/emitter moiety" as used herein refers to a species capable of absorbing  
35 light energy of one wavelength and emitting light energy of another wavelength. The term includes both phosphorescent and fluorescent species. In choosing the particular absorber/emitter for a given

reagent system, it is necessary that it possess absorbance in the spectral region of the light produced by the chemiluminescent catalyst (or the first absorber/emitter moiety, as the case may be).  
5 It is preferable that the emission of the absorber/emitter be of a long enough wavelength to be effectively distinguished from the chemiluminescence emitted by the reagent system.

For example, two chemiluminescent reactions of  
10 primary interest are luminol oxidation by hydrogen peroxide and aldehyde oxygenation (e.g. isobutyraldehyde and propanal). Both of these reactions are catalyzed by peroxidase. Suitable  
absorber/emitters for the luminol chemiluminescent  
15 reaction include free base porphyrins such as uroporphyrin and tetracarboxyphenylporphyrin, metalloporphyrins containing such metals as magnesium or zinc, tetraphenylcarboxyporphyrins,  
20 perylene, anthracene, 7-methyldibenzo (a,h) pyrene, and other polycyclic aromatics having conjugated ring systems of sufficient size to produce strong absorbance in the region of luminol chemiluminescence (between 400 and 450 nm). The absorber/emitters  
may be easily sulfonated and activated for conjugation  
25 by formation of the sulfonic acid chlorides by general synthetic procedures. Also, carboxylation may be performed if required. Suitable absorber/emitters for the chemiluminescence resulting from aldehyde oxygenation include the above-mentioned porphyrins  
30 and polynuclear aromatics. However, halogenation of the polynuclear aromatics is required in order to provide efficient transfer of energy from the chemiluminescent emitter since it emits from a triplet excited state. Examples of appropriate halogenated  
35 polynuclear aromatics are 9,10-dibromoanthracene, 9,10-dibromo-2,6-anthracene disulfonic acid, 3,10-dibromo-4,9-perylene dicarboxylate, and 3,9- or


3,10-dibromoperylene. If required, sulfonation or carboxylation as described are also easily performed on these compounds by general synthetic procedures.

In cases where both the first and second ss-  
5 polynucleotide reagent segments are to be labeled with absorber/emitter moieties, combinations of fluorescent compounds such as an etheno-nucleotide with a tetracarboxyerylene derivative or a fluorescein derivative with a rhodamine derivative  
10 can be used. Criteria for choosing absorber/emitter pairs are: (1) the absorber/emitter moiety on one reagent strand should have good absorption of light in the emission region of the absorber/emitter moiety on the second strand; (2) the final emission  
15 (fluorescence) should be strong and have a maximum sufficiently longer than that of the maximum of the first emission; and (3) both moieties should have properties which will allow them to be easily functionalized and coupled to the reagent strands.

20 The term "chemiluminescent catalyst" includes any of a variety of light emitting species which can be covalently attached to the ss-polynucleotide reagent segment. Such labels include those of both the chemiluminescent and bioluminescent types and  
25 as used herein the term "chemiluminescent" shall include the closely related term "bioluminescent." Chemiluminescent catalysts useful within the scope of this invention include peroxidase, bacterial luciferase, firefly luciferase, functionalized iron-  
30 porphyrin derivatives, and others. Choice of the chemiluminescent label or catalyst depends on several factors, which include: (1) hybridization conditions to be used, particularly temperature; (2) method to be used for covalent coupling to the ss-polynucleotide reagent segment; and (3) size of the ss-polynucleotide  
35 reagent segment. The chemiluminescent reagents effective for inducing light emission from the


chemiluminescent catalysts will depend upon the particular chemiluminescent catalyst being used and are well documented in the literature (Methods in Enzymology, Vol. LVII, M. A. Deluca (Ed.), 1978).

- 5 For example, the following reaction illustrates how light is emitted in the presence of a peroxidase catalyst:




- The chemiluminescent agents effective for inducing light emission in this instance would comprise hydrogen peroxide and luminol. Other agents which could be used  
15 include isobutyraldehyde and oxygen.

Similar reagent systems are suggested by the following reactions using other chemiluminescent catalysts:



- wherein  $\text{FMNH}_2$  is reduced flavin mononucleotide, R is a straight carbon chain having from 8 to 12  
25 carbons, and FMN is flavin mononucleotide.



- 30 wherein ATP is adenosine triphosphate, AMP is adenosine monophosphate, and PPI is inorganic phosphates.

- The "target" ss-polynucleotide is a segment of either one of the two complimentary strands of the  
35 double-stranded nucleic acid from the organism for which the assay is being conducted. It contains the unique polynucleotide sequence by which the

organism itself or certain genetic traits can be identified.

The first and second ss-polynucleotide reagent segments must consist essentially of bases which are complementary to the base sequence of the target ss-polynucleotide. It is necessary that the first and second segments be complementary to substantially mutually exclusive portions of the target ss-polynucleotide. In other words, upon hybridization with the target polynucleotide the first and second reagent segments should not compete for the same base sequence to the extent that hybridization is prevented. That is, the first and second segments will line up head to tail (3' end to 5' end) with no overlap and with few or no base-pairing spaces left between them. First and second ss-polynucleotide reagent segments can be made from appropriate restriction endonuclease treated nucleic acid from the organism of interest or, in cases where the base sequence of a unique portion is known, they can be synthesized by organic synthetic techniques (Stawinski, J. et al., Nuc. Acids Res. 4, 353, 1977; Gough, G. R. et al., Nuc. Acids Res. 6, 1557, 1979; Gough, G. R. et al., Nuc. Acids Res. 7, 1955, 1979; Narang, S. A., Methods in Enzymology, Vol. 65, Part I, 610-620, 1980). Also, it is possible to produce oligodeoxyribonucleotides of defined sequence using polynucleotide phosphorylase (E. Coli) under proper conditions (Gillam, S., and Smith, M., Methods in Enzymology, Vol. 65, Part I, pp. 687-701, 1980).

The first and second ss-polynucleotide reagent segments are generally labeled with their appropriate moieties in the 3' terminal position and 5' terminal position respectively, that is, the 3' terminal position of one strand that will become continuous (line up head to tail) with the 5' terminal position

of the other strand. Labeling of the 3' or 5' position with either chemiluminescent catalyst or a given absorber/emitter moiety is arbitrary. In general it will depend on the given moiety and method of the coupling reaction.

5       The size of the reagent segments can be from 10 nucleotides to 100,000 nucleotides in length. Below 10 nucleotides, hybridized systems are not stable and will begin to denature above 20°C. Above 100,000 nucleotides, one finds that hybridization (renaturation) becomes a much slower and incomplete process, see (Molecular Genetics, Stent, G. S and R. Calender, pp. 213-219, 1971). Ideally the reagent segments should be from 20 to 10,000 10       nucleotides. Smaller nucleotide sequences (20-100) would lend themselves to production by automated organic synthetic techniques. Sequences from 100-10,000 nucleotides could be obtained from appropriate restriction endonuclease treatments. 15       The labeling of the smaller segments with the relatively bulky chemiluminescent moieties may in some cases interfere with the hybridization process. In these cases it may be advantageous to use both reagent segments with appropriate absorber/emitter 20       moieties. 25       

      The proper hybridization conditions will be determined by the nature of the light label attached to the reagent polynucleotide sequences, the size of the reagent polynucleotide sequences, 30       the [G] + [C] (guanine plus cytosine) content of the reagent and sample polynucleotide sequences, and how the sample polynucleotide sequence is prepared. The light label can affect the temperature and salt concentration used for 35       carrying out the hybridization reaction. Chemiluminescent catalysts can be sensitive to temperatures and salt concentrations that

absorber/emitter moieties can tolerate. The size of the reagent polynucleotide sequences affects the temperature and time for the hybridization reaction. Assuming similar salt and reagent concentrations, hybridizations involving reagent polynucleotide sequences in the range of 10,000 to 100,000 nucleotides might require from 40 to 80 minutes to occur at 67°C, while hybridizations involving 20 to 100 nucleotides would require from 5 to 30 minutes at 25°C. Similarly, [G] + [C] content of the reagent and sample polynucleotide sequences affects the temperature and time for the hybridization reaction. Polynucleotide sequences with a high [G] + [C] content will hybridize at lower temperatures in a shorter period of time than polynucleotide sequences with a low [G] + [C] content. Finally, conditions used to prepare the sample polynucleotide sequence and maintain it in the single-stranded form can affect the temperature, time, and salt concentration used in the hybridization reaction. The conditions for preparing the sample polynucleotide sequence are affected by the polynucleotide length required and the [G] + [C] content. In general, the longer the sequence or the higher the [G] + [C] content, the higher the temperature and/or salt concentration required.

#### BRIEF DESCRIPTION OF THE DRAWING

Figure 1 illustrates the preparation of first and second ss-polynucleotide reagent segments labeled with chemiluminescent catalyst and absorber/emitter moieties for use as reagents in carrying out an assay for antibiotic resistance.

Figure 2 illustrates the interaction between the sample and the first and second reagent ss-polynucleotide reagent segments, showing how the presence of the target ss-polynucleotide causes induced light emission (fluorescence).

DISCUSSION

Directing attention to the Drawing, the invention will be described in greater detail. In Figure 1, the preparation of reagent ss-poly-nucleotides for assaying the presence of the  
5 antibiotic resistance gene, for example, is illustrated. Generally speaking, the most practical means to prepare the first and second reagent segments is to first isolate the particular polynucleotide  
10 containing the unique sequence of interest. In this case, for example, the antibiotic resistance gene located in a bacterial plasmid is obtained by subjecting the plasmid to the action of appropriate restriction enzymes. The gene of interest is sep-  
15 arated from the other fragments by suitable methods, such as gel electrophoresis.

The isolated gene is then cut into two or more segments having contiguous ends by further action of an appropriate restriction enzyme. It is prefer-  
20 able to have only two segments of roughly equal size for matters of convenience and simplicity, but more than two segments can also be used equally well. The two gene segments have been labeled X and Y in the Drawing for purposes of identification.  
25 Also, each polynucleotide strand of each segment is labeled (+) or (-) for further identification. The two segments are denatured to liberate the four different ss-polynucleotide segments. At this point it is necessary to remove either the (+) segments  
30 or the (-) segments. Unless circumstances suggest otherwise, the choice is arbitrary. Figure 1 shows removal of the X(-) and Y(-) strands, leaving the X(+) and Y(+) strands, which represent first and  
35 second ss-polynucleotide segments which are complementary to mutually exclusive portions of the target ss-polynucleotide from which they were separated. (The base sequence of the original single-

strand comprising the X(-) and Y(-) strands becomes the "target" ss-polynucleotide, whose presence in a ss-polynucleotide sample represents the presence of the antibiotic resistance (target) gene in the original

5 physiological sample.) Removal of the X(-) and Y(-) strands is most easily accomplished by exposing the strands to immobilized X(+) and Y(+) segments under hybridization conditions. Under such conditions the X(-) and Y(-) strands bond to the immobilized  
10 segments and can easily be removed from the system.

The contiguous ends of the remaining X(+) and Y(+) gene segments are then 5'-terminal and 3'-terminal labeled. The X(+) gene segment is 5'-terminal labeled with the chemiluminescent catalyst  
15 (CL) and the Y(+) gene segment is 3'-terminal labeled with an absorber/emitter moiety (A/E). These labeled strands become the first and second ss-polynucleotide reagent segments respectively. Upon hybridization, the chemiluminescent catalyst and the absorber/emitter  
20 moiety will be positioned closely enough to permit efficient non-radiative energy transfer, generally within about 100A or less of each other. In practice it may or may not be necessary to limit the labeling to the contiguous ends since the presence  
25 of extra labels at the other ends of the segment will not adversely affect the assay, unless they are within 100A or less of each other where energy-transfer can begin to take place. Therefore, for 22-polynucleotide reagent segments which are less  
30 than about 30 nucleotides (~90-100A) in length, only contiguous ends should be labeled. For segments which are more than 30 nucleotides (~100A) in length, both ends can be labeled. In the latter case, all 5'-termini (X(+) and Y(+)) could be labeled  
35 with chemiluminescent catalysts and all 3'-termini (X(+) and Y(+)) could be absorber/emitter labeled. The decision to label 5'-terminal positions with

chemiluminescent catalysts and 3'-terminal positions with absorber/emitter moieties, or visa versa, is arbitrary and determined by the functionality of the derivatives and coupling methods available.

5       As an example, the 3'-termini of the X(+) and Y(+) segments can be labeled with aminohexane-3'-5'-adenosine diphosphate using RNA ligase or with aminohexane-5'-adenosine diphosphate using polynucleotide phosphorylase under special conditions.

10      The strands would contain an aminohexyl functional group at the 3'-termini through which a variety of absorber/emitter moieties could be easily attached. Coupling of a chemiluminescent catalyst, such as peroxidase, to the 5'-termini involves the synthesis

15      of a short oligonucleotide linker segment. The segments contain an aminohexane-adenosine nucleotide at the 5'-termini followed by a short sequence of about four to six adenosine or thymidine nucleotides. This linker segment can now be attached to the 5'-

20      termini position of the X(+) and Y(+) segments through the appropriate use of basic ligation reactions, which are commonly used in recombinant DNA technology for plasmid construction.

25      Figure 2 illustrates how the two ss-polynucleotide reagent segments interact with the sample ss-polynucleotides in performing the assay. Some sample preparation is necessary to free the DNA or RNA from its cells in the physiological sample. Preferably the polynucleotides from the original

30      physiological sample are isolated to form a more concentrated sample. Sample DNA that has been isolated must be denatured to form a "single-stranded polynucleotide sample." This is the sample on which the assay of this invention is

35      performed. Regardless of which strands ((+) or (-)) were used in preparing the first and second reagent segments, the ss-polynucleotide sample will

contain the complementary strand if the gene being assayed was originally present. Figure 2 illustrates hybridization taking place when the ss-polynucleotide sample is contacted with the two reagent segments

5 and the other chemiluminescent reagents. Such hybridization places the absorber/emitter in close proximity to the chemiluminescent catalyst such that non-radiative energy transfer can take place. This transfer of chemiluminescent energy excites  
10 the absorber/emitter and fluorescent light, for example, is emitted as shown. All light from the assay is preferably filtered to remove background chemiluminescence and is detected by a photo-multiplier tube. For purposes of simplicity, it is  
15 preferable to have all of the reagents in one solution so that the only physical steps involved in the assay are to add the ss-polynucleotide sample and detect the light emitted, if any. However, it is also suitable to carry out the hybridization  
20 first, followed by further addition of the other chemiluminescent reagents necessary to create the chemiluminescent light response from the first ss-polynucleotide segment.

In cases where both the first and second ss-  
25 polynucleotide reagent segments are both absorber/emitter-labeled, the first absorber/emitter is irradiated with light at the appropriate wavelength and the second absorber/emitter emission wavelength is monitored for determining degree of hybridization.

30 It will be appreciated by those skilled in the art that many variations from this example, shown only for purposes of illustration, can be made without departing from the scope of this invention.

We claim:

1. A method for assaying a unique polynucleotide sequence or gene segment comprising:
  - a) contacting a single-stranded  
5 polynucleotide sample, under hybridization conditions, with first and second single-stranded polynucleotide reagent segments which are complementary to substantially mutually exclusive portions of a target  
10 single-stranded polynucleotide, said first reagent segment having a chemiluminescent catalyst attached thereto and said second reagent segment having an absorber/emitter moiety attached thereto, such that upon  
15 hybridization with a target single-stranded polynucleotide, the chemiluminescent catalyst and the absorber/emitter moiety would be close enough to each other to permit non-radiative energy transfer;
  - 20 b) further contacting the single-stranded polynucleotide sample with chemiluminescent reagents effective for causing light emission in the presence of the chemiluminescent catalyst; and
  - 25 c) measuring the quantity of light emitted by the absorber/emitter moiety.
2. The method of Claim 1 wherein the single-stranded polynucleotide sample is contacted with the first and second polynucleotide reagent segments  
30 prior to being contacted with the chemiluminescent reagents.
3. The method of Claim 1/<sup>or Claim 2</sup> wherein the chemiluminescent catalyst is selected from the group consisting of peroxidase and luciferases.
- 35 4. The method of Claim 1/<sup>or Claim 2</sup> wherein the absorber/emitter moiety is selected from the group consisting of fluorophores and phosphores.


- any preceding claim
5. The method of ~~Claim 1~~ wherein the first and second single-stranded polynucleotide reagent segments are obtained by:
- a) ~~cleaving double-stranded target~~  
5 polynucleotides in a physiological sample to form polynucleotide segments;
- b) denaturing the polynucleotide segments to obtain single-stranded polynucleotide segments;
- 10 c) end labeling the 3' ends of the polynucleotide segments with either a chemiluminescent catalyst or an absorber/emitter moiety; and
- d) end labeling the 5' ends of the polynucleotide segments with the catalyst or moiety not used in step (c).
- 15
6. The method of Claim 5 wherein the chemiluminescent catalyst is attached to the 5' ends of the polynucleotide reagent segments and the absorber/emitter moiety is attached to the 3' ends of the polynucleotide reagent segments.
- 20
7. The method of Claim 5 wherein the chemiluminescent catalyst is attached to the 3' ends of the polynucleotide segments and the absorber/emitter moiety is attached to the 5' ends of the polynucleotide segments.
- 25
8. A reagent for detecting the presence of a target single-stranded polynucleotide in a single-stranded polynucleotide sample comprising:
- 30 a) a first single-stranded polynucleotide reagent segment having at least one chemiluminescent catalyst attached thereto and which is complementary to a portion
- 35 of a target single-stranded polynucleotide;

- 5           b) a second single-stranded polynucleotide reagent segment having at least one absorber/emitter moiety attached thereto and which is complementary to a different, substantially mutually exclusive portion of the target single-stranded polynucleotide; and
- 10           c) chemiluminescent reagents effective for causing light emission in the presence of the chemiluminescent catalyst.
9. The reagent of Claim 8 wherein a chemiluminescent catalyst is attached at an end of the first single-stranded polynucleotide reagent segment.
- 15   10. The reagent of Claim 8 wherein an absorber/emitter moiety is attached at an end of the second single-stranded polynucleotide reagent segment.
11. The reagent of Claim 8 wherein the first single-stranded polynucleotide reagent segment contains
- 20           a chemiluminescent catalyst and an absorber/emitter moiety.
12. The reagent of Claim 8 wherein both the first and second single-stranded polynucleotide reagent segments contain a chemiluminescent catalyst
- 25           and an absorber/emitter moiety.
13. The reagent of Claim 12 wherein the chemiluminescent catalyst and the absorber/emitter moiety are attached to the ends of both the first and second polynucleotide reagent segments.
- 30   14. The reagent of Claim 13 wherein the chemiluminescent catalyst is attached at the 3' end of the first and second single-stranded polynucleotide reagent segments and an absorber/emitter moiety is attached at the 5' end of the first
- 35           and second single-stranded polynucleotide reagent segments.

15. The reagent of <sup>any one of Claims 8 to 14</sup>~~Claim 14~~ wherein the chemiluminescent catalyst is selected from the group consisting of peroxidase and luciferases.
- 5 16. The reagent of <sup>any one of Claims 8 to 14</sup>~~Claim 14~~ wherein the absorber/emitter moiety is selected from the group consisting of fluorophores and phosphores.
17. A method for assaying a unique polynucleotide sequence or gene segment comprising:
- 10 a) contacting a single-stranded polynucleotide sample, under hybridization conditions, with a reagent solution comprising first and second single-stranded polynucleotide segments which are complementary to substantially mutually exclusive portions of a target single-stranded polynucleotide, both of said first and second segments having a different absorber/emitter moiety attached thereto, such that upon hybridization with a target single-stranded polynucleotide the absorber/emitter moieties would be close enough to each other to permit non-radiative energy transfer;
- 15 b) irradiating the sample with light sufficient to excite one of the absorber/emitter moieties; and
- 20 c) measuring the light response from the other absorber/emitter moiety.
- 25 18. A reagent solution comprising first and second single-stranded polynucleotide segments which are complementary to substantially mutually exclusive portions of a target single-stranded polynucleotide, both of said first and second segments having a different absorber/emitter moiety attached thereto, such that upon hybridization with a target single-stranded polynucleotide the absorber/emitter moieties would be close enough to each other to permit non-radiative energy transfer.
- 30
- 35

# Fig. 1. PREPARATION OF SINGLE-STRANDED POLYNUCLEOTIDE REAGENT SEGMENTS FOR ASSAYING ANTIBIOTIC RESISTANCE

- ① ISOLATION AND RESTRICTION OF DNA OF INTEREST




RESISTANCE GENE

RESTRICTION  
ENDONUCLEASE

- ② ISOLATION OF THE RESISTANCE GENE




- ③ CLEAVAGE OF RESISTANCE GENE INTO TWO PIECES X AND Y




- ④ ISOLATION OF (+) STRANDS

DENATURE


REMOVE X(-) AND Y(-) STRAND



- ⑤ END LABELING WITH CHEMILUMINESCENT AND ABSORBER/EMITTER MOIETIES




5'-CHEMILUMINESCENT  
LABELED X(+) STRAND




3'-ABSORBER/EMITTER  
LABELED Y(+) STRAND

Fig. 2.


- ① ISOLATION OF  
DNA FROM  
SAMPLE




- ③ ADDITION OF SINGLE-STRANDED  
POLYNUCLEOTIDE REAGENT  
SEGMENTS AND HYBRIDIZATION



- ② DENATURATION



- ④ HYBRIDIZATION OCCURS  
BETWEEN REAGENT  
STRANDS AND COMPLIMENT-  
ARY STRAND FROM SAMPLE  
PROXIMATING THE CHEMI-  
LUMINESCENT AND  
ABSORBER/EMITTER  
MOIETIES.



- ⑤ DETECTION  
OF INDUCED  
FLUORESCENCE

